Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Trump's Drug Pricing Blueprint: An Administrative Vs. Legislative Breakdown

Jun 12 2018

• By Michael Cipriano

Capitol House

Related Content

How Drug Promotion Might Change Under Trump's Rx Pricing Plan

May 14 2018

Drug Firms Fear PBM ‘Discrimination’ Over List Price Reductions, Azar Tells Hearing

Jun 12 2018

Waivers For Shared REMS Will Depend On Impact To Generics, Docs, Patients

Jun 01 2018

Shared REMS: US FDA Wants Brisk Brand-Generic Talks, Might Give Unilateral Waivers

Jun 01 2018

A World Without Rebates: Is FDA’s Gottlieb Offering New Vision?

May 09 2018

Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model

May 12 2018

Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan

May 15 2018

US FDA's Abram Makes The Case For 180-Day Exclusivity Reform

Feb 14 2018

Additional Topics

United States Pricing Debate Policy Legislation BioPharmaceutical

More from Pricing Debate

More from Market Access

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window